Risk prediction models for lung cancer in people who have never smoked: a protocol of a systematic review
Tóm tắt
Lung cancer is one of the most commonly diagnosed cancers and the leading cause of cancer-related death worldwide. Although smoking is the primary cause of the cancer, lung cancer is also commonly diagnosed in people who have never smoked. Currently, the proportion of people who have never smoked diagnosed with lung cancer is increasing. Despite this alarming trend, this population is ineligible for lung screening. With the increasing proportion of people who have never smoked among lung cancer cases, there is a pressing need to develop prediction models to identify high-risk people who have never smoked and include them in lung cancer screening programs. Thus, our systematic review is intended to provide a comprehensive summary of the evidence on existing risk prediction models for lung cancer in people who have never smoked. Electronic searches will be conducted in MEDLINE (Ovid), Embase (Ovid), Web of Science Core Collection (Clarivate Analytics), Scopus, and Europe PMC and Open-Access Theses and Dissertations databases. Two reviewers will independently perform title and abstract screening, full-text review, and data extraction using the Covidence review platform. Data extraction will be performed based on the Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS). The risk of bias will be evaluated independently by two reviewers using the Prediction model Risk-of-Bias Assessment Tool (PROBAST) tool. If a sufficient number of studies are identified to have externally validated the same prediction model, we will combine model performance measures to evaluate the model’s average predictive accuracy (e.g., calibration, discrimination) across diverse settings and populations and explore sources of heterogeneity. The results of the review will identify risk prediction models for lung cancer in people who have never smoked. These will be useful for researchers planning to develop novel prediction models, and for clinical practitioners and policy makers seeking guidance for clinical decision-making and the formulation of future lung cancer screening strategies for people who have never smoked. This protocol has been registered in PROSPERO under the registration number CRD42023483824.
Tài liệu tham khảo
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
SEER Cancer Stat Facts: Lung and Bronchus Cancer: National Cancer Institute. Bethesda, MD. Available from: https://seer.cancer.gov/statfacts/html/lungb.html. Accessed 5 Feb 2024.
SEER*Explorer: an interactive website for SEER cancer statistics [Internet]: surveillance research program, National Cancer Institute; 2023 Apr 19. (updated: 2023 Jun 8). Accessed 26 Oct 2023. Available from: https://seer.cancer.gov/statistics-network/explorer/. Data source(s): SEER Incidence Data, November 2022 Submission (1975–2020), SEER 22 registries (excluding Illinois and Massachusetts). Expected Survival Life Tables by Socio-Economic Standards.
Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 2000;321(7257):323–9.
Zhang B, Ferrence R, Cohen J, Bondy S, Ashley MJ, Rehm J, et al. Smoking cessation and lung cancer mortality in a cohort of middle-aged Canadian women. Ann Epidemiol. 2005;15(4):302–9.
Su Z, Jia X-H, Zhao F-H, Zhou Q-H, Fan Y-G, Qiao Y-L. Effect of time since smoking cessation on lung cancer incidence: an occupational cohort with 27 follow-up years. Front Oncol. 2022;12:817045.
Khuder SA, Mutgi AB. Effect of smoking cessation on major histologic types of lung cancer. Chest. 2001;120(5):1577–83.
Tse LA, Lin X, Li W, Qiu H, Chan CK, Wang F, et al. Smoking cessation sharply reduced lung cancer mortality in a historical cohort of 3185 Chinese silicotic workers from 1981 to 2014. Br J Cancer. 2018;119(12):1557–62.
Pelosof L, Ahn C, Gao A, Horn L, Madrigales A, Cox J, et al. Proportion of never-smoker non–small cell lung cancer patients at three diverse institutions. J Natl Cancer Inst. 2017;109(7):djw295.
Cufari ME, Proli C, De Sousa P, Raubenheimer H, Al Sahaf M, Chavan H, et al. Increasing frequency of non-smoking lung cancer: presentation of patients with early disease to a tertiary institution in the UK. Eur J Cancer. 2017;84:55–9.
Poirier AE, Ruan Y, Grevers X, Walter SD, Villeneuve PJ, Friedenreich CM, et al. Estimates of the current and future burden of cancer attributable to active and passive tobacco smoking in Canada. Prev Med. 2019;122:9–19.
Cancer Statistics for the UK. Cancer Research UK. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/common-cancers-compared. Accessed 5 Feb 2024.
Chen W, Xia C, Zheng R, Zhou M, Lin C, Zeng H, et al. Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment. Lancet Glob Health. 2019;7(2):e257–69.
Wang J-B, Jiang Y, Wei W-Q, Yang G-H, Qiao Y-L, Boffetta P. Estimation of cancer incidence and mortality attributable to smoking in China. Cancer Causes Control. 2010;21:959–65.
Malhotra J, Malvezzi M, Negri E, La Vecchia C, Boffetta P. Risk factors for lung cancer worldwide. Eur Respir J. 2016;48(3):889–902.
Dubin S, Griffin D. Lung cancer in non-smokers. Missouri medicine. 2020;117(4):375.
Besaratinia A, Pfeifer GP. Second-hand smoke and human lung cancer. Lancet Oncol. 2008;9(7):657–66.
Hori M, Tanaka H, Wakai K, Sasazuki S, Katanoda K. Secondhand smoke exposure and risk of lung cancer in Japan: a systematic review and meta-analysis of epidemiologic studies. Jpn J Clin Oncol. 2016;46(10):942–51.
Huang F, Pan B, Wu J, Chen E, Chen L. Relationship between exposure to PM2. 5 and lung cancer incidence and mortality: a meta-analysis. Oncotarget. 2017;8(26):43322.
Myers R, Brauer M, Dummer T, Atkar-Khattra S, Yee J, Melosky B, et al. High-ambient air pollution exposure among never smokers versus ever smokers with lung cancer. J Thorac Oncol. 2021;16(11):1850–8.
Silverman DT, Samanic CM, Lubin JH, Blair AE, Stewart PA, Vermeulen R, et al. The diesel exhaust in miners study: a nested case–control study of lung cancer and diesel exhaust. J Natl Cancer Inst. 2012;104(11):855–68.
Hosgood HD III, Wei H, Sapkota A, Choudhury I, Bruce N, Smith KR, et al. Household coal use and lung cancer: systematic review and meta-analysis of case–control studies, with an emphasis on geographic variation. Int J Epidemiol. 2011;40(3):719–28.
Collaborators G, Ärnlöv J. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223–49.
Whitaker K. Earlier diagnosis: the importance of cancer symptoms. Lancet Oncol. 2020;21(1):6–8.
Spitz MR, Hong WK, Amos CI, Wu X, Schabath MB, Dong Q, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst. 2007;99(9):715–26.
Tammemagi CM, Pinsky PF, Caporaso NE, Kvale PA, Hocking WG, Church TR, et al. Lung cancer risk prediction: prostate, lung, colorectal and ovarian cancer screening trial models and validation. J Natl Cancer Inst. 2011;103(13):1058–68.
Park S, Nam B-H, Yang H-R, Lee JA, Lim H, Han JT, et al. Individualized risk prediction model for lung cancer in Korean men. PLoS ONE. 2013;8(2): e54823.
Kramer BS, Berg CD, Aberle DR, Prorok PC. Lung cancer screening with low-dose helical CT: results from the National Lung Screening Trial (NLST). London, England: SAGE Publications Sage UK; 2011. p. 109–11.
Infante M, Cavuto S, Lutman FR, Passera E, Chiarenza M, Chiesa G, et al. Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography. Am J Respir Crit Care Med. 2015;191(10):1166–75.
Field JK, Vulkan D, Davies MP, Duffy SW, Gabe R. Liverpool Lung Project lung cancer risk stratification model: calibration and prospective validation. Thorax. 2021;76(2):161–8.
Field JK, Vulkan D, Davies MP, Baldwin DR, Brain KE, Devaraj A, et al. Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis. Lancet Reg Health Europe. 2021;10:100179.
Wender R, Fontham ET, Barrera E Jr, Colditz GA, Church TR, Ettinger DS, et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013;63(2):106–17.
Kerpel-Fronius A, Tammemägi M, Cavic M, Henschke C, Jiang L, Kazerooni E, et al. Screening for lung cancer in individuals who never smoked: an international association for the study of lung cancer early detection and screening committee report. J Thorac Oncol. 2022;17(1):56–66.
Tammemaegi MC, Church TR, Hocking WG, Silvestri GA, Kvale PA, Riley TL, et al. Evaluation of the lung cancer risks at which to screen ever-and never-smokers: screening rules applied to the PLCO and NLST cohorts. PLoS Med. 2014;11(12):e1001764.
Wu X, Wen CP, Ye Y, Tsai M, Wen C, Roth JA, et al. Personalized risk assessment in never, light, and heavy smokers in a prospective cohort in Taiwan. Sci Rep. 2016;6(1):36482.
Warkentin MT, Lam S, Hung RJ. Determinants of impaired lung function and lung cancer prediction among never-smokers in the UK Biobank cohort. EBioMedicine. 2019;47:58–64.
Chien L-H, Chen C-H, Chen T-Y, Chang G-C, Tsai Y-H, Hsiao C-F, et al. Predicting lung cancer occurrence in never-smoking females in Asia: TNSF-SQ, a prediction model. Cancer Epidemiol Biomark Prev. 2020;29(2):452–9.
Warkentin MT, Tammemägi MC, Espin-Garcia O, Budhathoki S, Liu G, Hung RJ. Lung Cancer absolute risk models for mortality in an Asian population using the China Kadoorie Biobank. J Natl Cancer Inst. 2022;114(12):1665–73.
Liao W, Coupland C, Burchardt J, Baldwin D, initiative D, Gleeson F, Hippisley-Cox J. Predicting the future risk of lung cancer: development and validation of QCancer2 (10-year risk) lung model and evaluating the model performance of nine prediction models. medRxiv. 2022:2022.06. 04.22275868.
Lan-Wei G. Lung cancer risk prediction nomogram in Chinese female non-smokers. Am Soc Clin Oncol. 2022;40(16_suppl):10530.
Peltola L, Nilsson M, Torkki P, Jekunen A, Andersén H, Leskelä R-L, Nuutinen M. A systematic review and meta-analysis of lung cancer risk prediction models. PROSPERO. 2022;CRD42022321391. Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022321391. Accessed 5 Feb 2024.
Juang YR, Seow WJ. Lung cancer risk prediction models in never-, formal- and current-smokers: a systematic review & meta-analysis. PROSPERO. 2022;CRD42022347087. Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022347087. Accessed 5 Feb 2024.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1–9.
Issanov A, Aravindakshan A, Puil L, Tammemägi M, Meza R, Lam S, Dummer T. Risk prediction models for lung cancer in people who have never smoked: a systematic review. PROSPERO. 2023;CRD420234838242023. Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023483824. Accessed 5 Feb 2024.
Moons KG, de Groot JA, Bouwmeester W, Vergouwe Y, Mallett S, Altman DG, et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. PLoS Med. 2014;11(10):e1001744.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.
Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) the TRIPOD statement. Circulation. 2015;131(2):211–9.
Wolff RF, Moons KG, Riley RD, Whiting PF, Westwood M, Collins GS, et al. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. Ann Intern Med. 2019;170(1):51–8.
IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14:1–12.
Debray T, de Jong V, Debray MT. Package ‘metamisc.’ 2019.
Viechtbauer W, Viechtbauer MW. Package ‘metafor’. The Comprehensive R Archive Network Package ‘metafor’. 2015. Available from: http://cran.r-project.org/web/packages/metafor/metaphor.pdf. Accessed 5 Feb 2024.
Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, et al. Discrimination and calibration of clinical prediction models: users’ guides to the medical literature. JAMA. 2017;318(14):1377–84.
Debray TPA, Damen JAAG, Snell KIE, Ensor J, Hooft L, Reitsma JB, et al. A guide to systematic review and meta-analysis of prediction model performance. BMJ. 2017;356:i6460.
Sterne JA, Egger M. Regression methods to detect publication and other bias in meta‐analysis. Publication bias in meta‐analysis: prevention, assessment and adjustments. 2005:99–110.
Snell KI, Levis B, Damen JA, Dhiman P, Debray TP, Hooft L, et al. Transparent reporting of multivariable prediction models for individual prognosis or diagnosis: checklist for systematic reviews and meta-analyses (TRIPOD-SRMA). BMJ. 2023;381:e073538.
Goldet G, Howick J. Understanding GRADE: an introduction. J Evid Based Med. 2013;6(1):50–4.
Iorio A, Spencer FA, Falavigna M, Alba C, Lang E, Burnand B, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ. 2015;350:h870.
Foroutan F, Guyatt G, Zuk V, Vandvik PO, Alba AC, Mustafa R, et al. GRADE guidelines 28: use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. J Clin Epidemiol. 2020;121:62–70.
Moriarty AS, Meader N, Snell KI, Riley RD, Paton LW, Chew-Graham CA, et al. Prognostic models for predicting relapse or recurrence of major depressive disorder in adults. Cochrane Database Syst Rev. 2021(5):CD013491.
Kreuzberger N, Damen JA, Trivella M, Estcourt LJ, Aldin A, Umlauff L, et al. Prognostic models for newly‐diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta‐analysis. Cochrane Database Syst Rev. 2020(7):CD012022.